These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 23538612)

  • 1. Management of fingolimod-associated macular edema.
    Chui J; Herkes GK; Chang A
    JAMA Ophthalmol; 2013 May; 131(5):694-6. PubMed ID: 23538612
    [No Abstract]   [Full Text] [Related]  

  • 2. Fingolimod-associated macular edema: resolution by sub-tenon injection of triamcinolone with continued fingolimod use.
    Minuk A; Belliveau MJ; Almeida DR; Dorrepaal SJ; Gale JS
    JAMA Ophthalmol; 2013 Jun; 131(6):802-4. PubMed ID: 23599188
    [No Abstract]   [Full Text] [Related]  

  • 3. Cystoid macular edema associated with fingolimod use for multiple sclerosis.
    Afshar AR; Fernandes JK; Patel RD; Ksiazek SM; Sheth VS; Reder AT; Hariprasad SM
    JAMA Ophthalmol; 2013 Jan; 131(1):103-7. PubMed ID: 23307220
    [No Abstract]   [Full Text] [Related]  

  • 4. Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis.
    Zarbin MA; Jampol LM; Jager RD; Reder AT; Francis G; Collins W; Tang D; Zhang X
    Ophthalmology; 2013 Jul; 120(7):1432-9. PubMed ID: 23531349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversible cystoid macular edema secondary to fingolimod in a renal transplant recipient.
    Saab G; Almony A; Blinder KJ; Schuessler R; Brennan DC
    Arch Ophthalmol; 2008 Jan; 126(1):140-1. PubMed ID: 18195237
    [No Abstract]   [Full Text] [Related]  

  • 6. Does fingolimod in multiple sclerosis patients cause macular edema?
    Turaka K; Bryan JS
    J Neurol; 2012 Feb; 259(2):386-8. PubMed ID: 22231867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fingolimod-associated macular edema: incidence, detection, and management.
    Jain N; Bhatti MT
    Neurology; 2012 Feb; 78(9):672-80. PubMed ID: 22371414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Background and rationale for mechanism of action, efficacy, and safety of fingolimod (Gilenya), the first oral therapy for remitting-relapsing multiple sclerosis: with special emphasis upon visual safety.
    Huggins A; Sergott RC
    Curr Opin Ophthalmol; 2011 Nov; 22(6):447-50. PubMed ID: 21946305
    [No Abstract]   [Full Text] [Related]  

  • 9. Use of intraocular ketorolac tromethamine for the treatment of chronic cystoid macular edema.
    Margalit E; Boysen JL; Zastrocky JP; Katz A
    Can J Ophthalmol; 2010 Aug; 45(4):409-10. PubMed ID: 20648080
    [No Abstract]   [Full Text] [Related]  

  • 10. [Cystoid macular oedema after fingolimod treatment in multiple sclerosis].
    Asensio-Sánchez VM; Trujillo-Guzmán L; Ramoa-Osorio R
    Arch Soc Esp Oftalmol; 2014 Mar; 89(3):104-6. PubMed ID: 24269406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of fingolimod in relapsing-remitting multiple sclerosis.
    Sorensen PS
    Lancet Neurol; 2014 Jun; 13(6):526-7. PubMed ID: 24685277
    [No Abstract]   [Full Text] [Related]  

  • 12. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
    Kappos L; Radue EW; O'Connor P; Polman C; Hohlfeld R; Calabresi P; Selmaj K; Agoropoulou C; Leyk M; Zhang-Auberson L; Burtin P;
    N Engl J Med; 2010 Feb; 362(5):387-401. PubMed ID: 20089952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fingolimod for multiple sclerosis.
    Drug Ther Bull; 2012 Feb; 50(2):18-20. PubMed ID: 22329953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fingolimod: an oral disease-modifying therapy for relapsing multiple sclerosis.
    Yeh EA; Weinstock-Guttman B
    Adv Ther; 2011 Apr; 28(4):270-8. PubMed ID: 21394595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sudden unexpected death on fingolimod.
    Lindsey JW; Haden-Pinneri K; Memon NB; Buja LM
    Mult Scler; 2012 Oct; 18(10):1507-8. PubMed ID: 22300970
    [No Abstract]   [Full Text] [Related]  

  • 16. Fingolimod-induced asthma deterioration in a patient with relapsing-remitting multiple sclerosis.
    van Rossum JA; Looysen EE; Daniels JM; Killestein J
    Mult Scler; 2014 Nov; 20(13):1792-3. PubMed ID: 24866203
    [No Abstract]   [Full Text] [Related]  

  • 17. Fingolimod for the treatment of relapsing multiple sclerosis.
    Jeffery DR; Markowitz CE; Reder AT; Weinstock-Guttman B; Tobias K
    Expert Rev Neurother; 2011 Feb; 11(2):165-83. PubMed ID: 21158700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of prophylactic nonsteroidal antiinflammatory drugs on cystoid macular edema assessed using optical coherence tomography quantification of total macular volume after cataract surgery.
    Almeida DR; Johnson D; Hollands H; Smallman D; Baxter S; Eng KT; Kratky V; ten Hove MW; Sharma S; El-Defrawy S
    J Cataract Refract Surg; 2008 Jan; 34(1):64-9. PubMed ID: 18165083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fingolimod therapy and macular hemorrhage.
    Bhatti MT; Freedman SM; Mahmoud TH
    J Neuroophthalmol; 2013 Dec; 33(4):370-2. PubMed ID: 23845997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced fingolimod dosage treatment for patients with multiple sclerosis and lymphopenia or neutropenia.
    Tanaka M; Park K; Tanaka K
    Mult Scler; 2013 Aug; 19(9):1244-5. PubMed ID: 23322501
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.